查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553457

失眠治疗药物市场规模、份额、趋势分析报告：按类型、销售管道、地区、细分市场预测，2024-2030

Insomnia Therapeutics Market Size, Share & Trends Analysis Report By Type (Benzodiazepines, Nonbenzodiazepines, Antidepressants), By Sales Channel (Prescription, OTC), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格
简介目录

失眠治疗药物市场成长与趋势：

根据Grand View Research, Inc.的最新报告，预计2030年全球失眠治疗市场将达到37.4亿美元，2024年至2030年复合年增长率为4.4%。

这个市场主要是由取得专利的分子的存在、潜在的临床候选药物、不断上升的压力水平以及越来越多的难以入睡的老年人口推动的。失眠盛行率的增加、对该疾病的认识以及更安全药物的供应预计将推动收益成长。

据估计，失眠症影响着世界上约 35% 的人口。这种症状的不同模式包括难以开始和维持睡眠，通常伴随频繁和早醒，以及难以恢復睡眠。长期失眠会干扰日常生活，导致工作效率低落。如果不及时治疗，这种情况可能会导致严重的忧郁症和神经衰弱。

影响失眠治疗药物市场成长的因素包括压力水平上升、市场上专利分子的存在、临床管道中的潜在药物、技术先进的医疗设备的引进以及老年人口的增加等。人们对睡眠不足对日常生活影响的认识不断提高，预计将提高各种失眠治疗方法的采用率，从而导致失眠治疗市场的收益成长。

目前，广泛用于治疗失眠的药物包括非苯二氮非专利药物和抗忧郁症，儘管市面上也有Orexin拮抗剂和褪黑激素拮抗剂等新药。Eisai推出 lemborexant 预计将解决该领域未满足的医疗需求，并在预测期内推动市场成长。根据2015年联合国报告，到2030年，60岁及以上的人口预计将增加56%，达到约14亿。这些统计数据表明，人口老化正在加剧。由于该族群更容易睡眠不足，因此对失眠治疗药物的需求预计会增加。

失眠治疗药物市场报告亮点

  • 苯二氮平类药物占据市场主导地位，2023 年市场占有率为 28.9%。苯二氮平类药物可用于治疗与急性压力相关的失眠。
  • 由于失眠患者的增加，非处方药在 2023 年占据最大的市场收益占有率，为 61.4%。
  • 北美失眠治疗药物市场占主导地位，2023年市场占有率为35.4%。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 失眠治疗药物的变因、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 失眠治疗分析工具
    • 波特的分析
    • PESTEL分析

第四章失眠治疗药物市场：按类型估计和趋势分析

  • 细分仪表板
  • 失眠治疗药物市场：类型变异分析，2023 年和 2030 年
  • 苯二氮平类
  • 非苯二氮平类药物
  • 抗忧郁症
  • Orexin拮抗剂
  • 褪黑激素拮抗剂
  • 其他的

第五章失眠治疗药物市场：依销售管道估算及趋势分析

  • 细分仪表板
  • 失眠治疗药物市场：2023年及2030年销售管道波动分析
  • 处方笺
  • OTC

第六章 失眠治疗药物市场：区域估计与趋势分析

  • 2023 年和 2030 年按地区分類的失眠药物份额
  • 北美洲
    • 北美失眠药物估计与预测，2018-2030
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030 年欧洲失眠药物估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030 年亚太地区失眠药物估计与预测
    • 日本
    • 中国
    • 印度
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲失眠药物估计与预测，2018-2030 年
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 2018-2030 年中东和非洲失眠药物估计和预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Takeda Pharmaceutical Company Ltd.
    • Vanda Pharmaceuticals
    • Merck &Co., Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Mylan NV
    • Sumitomo Dainippon Pharma Co., Ltd
    • Sanofi
    • Paratek Pharmaceuticals Inc.
    • Ebb Therapeutics
简介目录
Product Code: GVR-2-68038-213-6

Insomnia Therapeutics Market Growth & Trends:

The global insomnia therapeutics market is expected to reach USD 3.74 billion by 2030, expanding at a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the presence of patented molecules, potential clinical pipeline candidates, rising stress level, and increase in geriatric population who find it difficult to fall asleep. Increase in prevalence of insomnia & awareness about this condition and availability of safer drugs are anticipated to fuel revenue growth.

Insomnia is estimated to affect approximately 35% of the global population. Different patterns of the condition include difficulty in sleep initiation and maintenance, which is generally accompanied with frequent awakenings & awakening too early with trouble sleeping again. Long-term insomnia can hamper everyday life, which may result in nonproductive work hours. If left untreated, this condition may lead to severe depression and nervous breakdown of the patient.

Factors influencing insomnia therapeutics market growth include rising stress level, presence of patented molecules in the market, potential drugs in clinical pipeline, introduction of technologically advanced medical devices, and growing geriatric population. Growing awareness about the impact of sleep deprivation on everyday life is anticipated to increase adoption rate of various treatments for insomnia, which is expected to lead to revenue growth of the insomnia therapeutics market.

Currently, widely adopted treatment options for insomnia include generic nonbenzodiazepines and antidepressants even though other novel agents such as orexin antagonists and melatonin antagonists are available in the market. Launch of Eisai's Lemborexant is expected to cater to unmet medical needs in this segment and fuel growth of this market over the forecast period. According to United Nations (UN) report in 2015, population in the age group of 60 years and above is projected to grow by 56% and is expected to reach around 1.4 billion by 2030. These statistics indicate the growing geriatric population. Since this population base is more susceptible to sleep deprivation, the demand for insomnia therapeutics is anticipated to increase.

Insomnia Therapeutics Market Report Highlights:

  • Benzodiazepines dominated the market and accounted for a market share of 28.9% in 2023. Benzodiazepines are useful for insomnia associated with acute stress.
  • Over-the-counter accounted for the largest market revenue share of 61.4% in 2023, owing to the increasing number of patients with insomnia.
  • The North America insomnia therapeutics market dominated the market in 2023 with a market share of 35.4%.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Insomnia Therapeutics Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Insomnia Therapeutics Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Insomnia Therapeutics Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Insomnia Therapeutics Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Benzodiazepines
    • 4.3.1. Benzodiazepines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Nonbenzodiazepines
    • 4.4.1. Nonbenzodiazepines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Antidepressants
    • 4.5.1. Antidepressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Orexin Antagonists
    • 4.6.1. Orexin Antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Melatonin Antagonists
    • 4.7.1. Melatonin Antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Insomnia Therapeutics Market: Sales Channel Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Insomnia Therapeutics Market: Sales Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Prescription
    • 5.3.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Over-the Counter
    • 5.4.1. Over-the Counter Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Insomnia Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Insomnia Therapeutics Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. U.K.
      • 6.3.2.1. U.K. Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Sweden Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. China Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Thailand
      • 6.4.6.1. Thailand Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Insomnia Therapeutics and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Takeda Pharmaceutical Company Ltd.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Vanda Pharmaceuticals
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Merck & Co., Inc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Pfizer Inc.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Teva Pharmaceutical Industries Ltd.
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. Mylan N.V.
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Sumitomo Dainippon Pharma Co., Ltd
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Sanofi
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Paratek Pharmaceuticals Inc.
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Ebb Therapeutics
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives